• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 10, 2017

View Archived Issues

Biopharmaceutical companies able to generate almost $16B in Q3

The amount of cash generated by global public and private biopharmaceutical companies was up significantly in the third quarter compared to the second quarter. Read More

Regulatory front

The EMA and the European Commission (EC) updated the annex to the EC guideline on labeling excipients used in human drugs, adding five new excipients that must be declared in the labeling and new safety warnings for 10 excipients already included in the annex. Read More

In the clinic

Evolus Inc., of Santa Barbara, Calif., presented data at the American Society of Plastic Surgeons meeting in Orlando, Fla., and the American Society for Dermatologic Surgery meeting in Chicago, from phase II and phase III studies of its botulinum toxin candidate, prabotulinumtoxinA 900 kilodalton neuromodulator, in glabellar lines. Read More

California law touted as just the first step in reining in drug prices

Framing it as a victory of the weak over the powerful and the poor over the rich, California Gov. Jerry Brown Monday signed into law a bill that will require transparency – from biopharma companies, that is – about price increases for prescription drugs. Read More

Zilretta mo betta: Opioids voided by better choices? Keep eye on Centrexion

Approval by the FDA of Flexion Therapeutics Inc.'s Zilretta whetted the appetite for more non-opioid drugs, the lack of which has left officials at pain-focused Centrexion Therapeutics Inc. "awestruck," Chief Medical Officer Randall Stevens told BioWorld. Read More

U.S. IPO wheels keep turning in Q4 as trio of biopharmas collectively seeks $278.25M

The platforms are distinct but the end game is identical. Rare disease company Allena Pharmaceuticals Inc., anti-infectives developer Spero Therapeutics LLC and cancer therapy hopeful Erytech Pharma SA filed for U.S. IPOs, joining Ablynx NV, which filed days earlier, to extend the biopharma trek to the public markets into the fourth quarter. Read More

Chinese government adds might to country's push for drug innovation

HONG KONG – China's State Council released a set of guidelines for innovation in new drug and medical device development. The new regulations round up some recent regulatory updates, providing substantial and practical guidance to further push the innovation in China's health care industry. Read More

Propanc banking on proenzymes aimed at cancer stem cells

PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers. The Melbourne-based company reported that recent studies show that the once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen reduced epithelial to mesenchymal transition (EMT) markers, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells. Read More

Financings

Strongbridge Biopharma plc, of Trevose, Pa., said it closed its underwritten public offering of 4 million ordinary shares for total net proceeds of approximately $23.4 million. Read More

Other news to note

Thrombogenics NV, of Leuven, Belgium, said preclinical data published in Experimental Eye Research testing the murine form of THR-317 in various animal models of diabetic retinopathy (DR) showed that the anti-PlGF antibody shared a common pharmacology toward vascular leakage in comparison to VEGF inhibitors, which are currently the standard of care for DR. Read More

Appointments and advancements

Provention Bio Inc., of Lebanon, N.J., appointed Andrew Drechsler chief financial officer; Francisco Leon chief scientific officer; and Eleanor "Leni" Ramos chief medical officer and chief operating officer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock

    BioWorld
    Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe